We are updating the BioProcess Containers (BPCs) used for our 1L pack sizes. Please refer to Cat. No. A40005291BA to purchase validation material in our new packaging.

CTS™ OpTmizer™ T Cell Expansion SFM, bag format

Zitierungen und Referenzen (5)

Gibco™

CTS™ OpTmizer™ T Cell Expansion SFM, bag format

Katalognummer	Menge
A1048503	1 Beutel

Katalognummer A1048503

Preis (EUR)

256,00

Menge:

1 Beutel

Preis (EUR)

256,00

Gibco™ OpTmizer™ CTS™ T-Zellen-Expansion-SFM wurde für das Wachstum und die Expansion humaner T-Lymphozyten entwickelt.OpTmizer™ CTS™ T-Zell Expansionsmedium ist ein serum- und xenofreies 1x-Vollmedium, bestehend aus OpTmizer™ T-Zell Expansions-Basalmedium (1 l-Beutel) und OpTmizer™ T-Zell Expansions-Supplement (26 ml), die vor der Verwendung gemischt werden.

•Erhält ähnliche Phänotypen und Funktionen wie T-Zellen, die in herkömmlichem Medium mit Serumergänzung kultiviert werden
• Konsistente Leistung bei der Unterstützung der T-Zell-Expansion
• Unterstützt Kulturen hoher Dichte in statischen und WAVE Bioreactor™ Kulturen
• Mit dieser cGMP-konform hergestellten Rezeptur und der begleitenden Dokumentation sind Sie für die klinische Forschung gerüstet

Vielseitig einsetzbare T-Zell-Kulturmedien
Optimizer™ CTS™ T-Zell Expansions-SFM wurde entwickelt, um Ergebnisse zu liefern, die herkömmlichen Medien mit Serumergänzung gleichwertig sind.Auf Wunsch kann dem Medium 2 % hitzeinaktiviertes Humanserum (Kat.-Nr. 34005-100) hinzugefügt werden, um die Lebensfähigkeit und Expansion zu verbessern.Die Verwendung von Serum und die erforderliche Menge sollten empirisch je nach der spezifischen T-Zellkulturanwendung bestimmt werden.

Bereit zur T Zell-Expansion
OpTmizer™ CTS™ T-Zell Expansions-SFM ist für die Expansion humaner T-Zellen konzipiert und ermöglicht CD3+-Dichten von > 3 x 10⁶ Zellen/ml bei statischen Bedingungen und > 2 x 10⁷ Zellen/ml in WAVE-Beuteln.Die Ergebnisse können je nach T-Zellen-Untergruppe variieren (z. B. Ag-spezifische Zellen).Die Bedingungen für spezifische T-Zellkulturanwendungen sollten empirisch bestimmt werden.

Stabilität des Vollmediums
Das vollständige Optimizer™ CTS™ T-Zell Expansions-SFM (Basal, Supplement und L-Glutamin) ist 4 Wochen lang stabil, wenn es im Dunkeln bei 2 – 8°C gelagert wird.

Vereinfachen Sie den Übergang in die klinische Forschung
Die Marke Gibco™ Cell Therapy Systems (CTS™) umfasst eine breite Palette von Produkten für die Verwendung in Zelltherapieanwendungen, einschließlich Medien, Reagenzien, Wachstumsfaktoren, Enzymen, Reagenzien für die Selektion und Expansion von Zellen und Geräte.Gibco™ CTS™ Produkte bieten:
•Geringerer Aufwand bei der Eignungsprüfung von Reagenzien
• Geeignete Analysenzertifikate und Herkunft enthalten
• Bequemer Zugriff zu unserem Drug Master File (DMF)

Specifications

ZelltypT-Zellen

KulturmilieuCO₂

Endotoxin-GehaltSehr gering

Antibiotika inklusiveKeine Antibiotika

Anorganische SalzeKalzium, Magnesium

ProdukttypZell-Expansion Serum-freies Medium (SFM)

Reinheits- oder QualitätsgradForschungsqualität

Menge1 Beutel

KlassifikationChemisch definiert, serumfrei, Xeno-frei

Culture TypeSuspensions-Zellkultur

FormFlüssig

Serum LevelSerumfrei

SterilitätSteril

Mit AdditivenHEPES, Phenolrot, Natriumpyruvat, Natriumhydrogencarbonat

Ohne AdditiveKein Glutamin

Unit SizeEach

Inhalt und Lagerung

OpTmizer™ T-Zellen-Expansionsbasalmedium (1 x Liter-Medienbeutel):Bei 2 bis 8 °C lagern.Vor Licht schützen.

OpTimizer™ T-Zellen-Expansionszusatz (1 x 26 ml):Bei 2 – 8 °C im Dunkeln lagern.

Häufig gestellte Fragen (FAQ)

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?

The CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) kit comes with OpTmizer T Cell Expansion Basal Medium and OpTmizer T Cell Expansion Supplement, which are mixed together prior to use. Depending on your protocol you may need to purchase T cell growth factors such as IL-2 (Cat. No. PHC0023) and L-glutamine (Cat. No. 25030) to form a complete medium. To boost growth of human T cells, human AB serum can be added. If desired, antibiotics such as Gentamicin (Cat. No. 15750), can also be added.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has been demonstrated to be effective for the ex vivo expansion of human CD3 T cells, including polyclonal T cell populations, antigen-specific T cells, tumor-infiltrating lymphocytes (TIL), cord blood T cells, regulatory T cells, T cells from HIV-infected donors, gene-modified T cells (both lenti- and MLV-based vectors), including cells of both the CD4+ and CD8+ phenotype.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has only been tested on human T cells.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?

The bottle and bag packaging formats of the medium have the same formulation.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CTS™ OpTmizer™ T Cell Expansion SFM, bag format FAQs

Zitierungen und Referenzen (5)

Zitierungen und Referenzen

Abstract

Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.

Authors:Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R

Journal:

PubMed ID:25671129

The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More

Bioengineering and serum free expansion of blood-derived ?d T cells.

Authors:Sutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT

Journal:Cytotherapy

PubMed ID:27260209

'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More

A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.

Authors:Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA

Journal:Hum Gene Ther Methods

PubMed ID:27897048

The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More

Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.

Authors:Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV

Journal:Vaccine

PubMed ID:28536029

CIGB-247 is a cancer therapeutic vaccine, based on recombinant modified human vascular endothelial growth factor (VEGF) as antigen, in combination with the adjuvant VSSP, a bacterially-derived adjuvant. The vaccine have demonstrated efficacy in several murine malignancy models. These studies supported the rationale for a phase I clinical trial where safety, ... More

Enhancing adoptive cancer immunotherapy with V?2Vd2 T cells through pulse zoledronate stimulation.

Authors:Nada MH, Wang H, Workalemahu G, Tanaka Y, Morita CT

Journal:J Immunother Cancer

PubMed ID:28239463

Human ?d T cells expressing V?2Vd2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with V?2Vd2 T cells has been used to treat cancer patients with partial and complete remissions. Most clinical trials and preclinical studies have ... More